FORE Biotherapeutics
FORE Biotherapeutics is a registration stage biotherapeutics company focused on developing targeted therapies for cancer patients. Their lead asset, plixorafenib, is a BRAF inhibitor designed to address treatment gaps in various tumor types.
Funding Round: Series D2
Funding Amount: $38M
Date: 22-May-2025
Investors: SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, 3B Future Health Fund
Markets: Biotech, Oncology, Therapeutics
HQ: Philadelphia, Pennsylvania, United States
Founded:
Website: https://www.fore.bio/
LinkedIn: https://www.linkedin.com/company/forebiotherapeutics
Twitter: https://x.com/ForeBiotx
Leave a Comment
Comments
No comments yet.